Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 28, 2025 07:00 ET | Source: Amphista Therapeutics

Amphista Therapeutics to showcase how its Targeted Glue™ technology is expanding the diversity of TPD medicines at the 8th Annual TPD & Induced Proximity Summit 2025

Presentation will showcase the novel mechanisms of degradation of Amphista's Targeted Glues™, which recruit diverse E3 ligases, including DCAF16 and FBXO22, expanding the diversity and opportunity...
October 27, 2025 06:00 ET | Source: Amphista Therapeutics

Amphista Therapeutics’ successful degradation of a key cancer target, BRD9, via a novel mechanism with DCAF16 E3 ligase published in Nature Communications

The publication reports the highly selective, DCAF16 E3 enabled degradation of BRD9 in vivo using Amphista’s proprietary, next generation Targeted Glue™ medicinal chemistry technologyAmphista’s...
July 16, 2025 07:00 ET | Source: Amphista Therapeutics

Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment

Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue™ degraders for oncology and immunology indications Cambridge, UK, 16 July 2025 – Amphista Therapeutics (“the Company” or...
September 03, 2024 07:00 ET | Source: Amphista Therapeutics

Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer

Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted Glue™ protein...
September 03, 2024 03:00 ET | Source: Amphista Therapeutics

Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer

Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted Glue™ protein...
May 23, 2024 07:00 ET | Source: Amphista Therapeutics

Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium

PRESS RELEASE Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium First presentation of a novel mechanism of...
January 24, 2024 07:00 ET | Source: Amphista Therapeutics

Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders

PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders First...
January 24, 2024 03:00 ET | Source: Amphista Therapeutics

Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders

PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders First...